Assembly Bio Stock Tumbles On Discontinuation Of Hepatitis B Trial
Assembly Biosciences Inc (NASDAQ:ASMB) has decided to discontinue the development of ABI-H2158 (2158) following the observation of elevated alanine transaminase (ALT) levels…
William Blair Downgrades Assembly Biosciences to Market Perform
William Blair analyst Raju Prasad downgrades Assembly Biosciences (NASDAQ:ASMB) from Outperform to Market Perform.
10 Stocks Moving In Wednesday’s After-Hours Session
Gainers
INmune Bio (NASDAQ: INMB) shares are trading higher after the company announced XPro has been found to decrease multiple species of Phospho Tau and improve neuroimaging biomarkers of myelination in patients with AD.
Assembly Biosciences Q2 EPS $(0.55) Down From $0.19 YoY
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.55) per share. This is a 389.47 percent decrease over earnings of $0.19 per share from the same period last year.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 15)
Stocks That Hit 52-Week Lows On Thursday
During the morning session on Thursday, 152 stocks hit new 52-week lows.
The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)